Condition
Advanced Malignant Pleural Mesothelioma
Estimated Enrollment: 26
Age Group: 18 Years to 75 Years (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: INCANOGAR2012-JA3
Study First Received: April 18, 2012
Last Updated: March 1, 2017
Estimated Primary Completion Date: December 2017
Primary Outcome Measures:
Evaluate adverse effects to 250 mg/m2 infusion gemcitabine|Progression Free Survival|overall survival
Sponsors and Collaborators:
Instituto Nacional de Cancerologia de Mexico|National Council of Science and Technology, Mexico
Website Link: https://ClinicalTrials.gov/show/NCT01869023
